【醫藥護人員場】活動議程
-
00:00
1.
Novel Therapies for Patients with Metastatic Prostate Cancer Part 1Cabazitaxel (Jevtana，去癌達)
-
00:07
2.
Outline
-
00:46
3.
In 2004 docetaxel &predsisone was established as the new standard of care for patients that progressed on ADT
-
02:23
4.
Cabazitaxel (JEVTANA®): a next-generation taxane
-
03:16
5.
Mode of action of Cabazitaxel
-
04:03
6.
Cabazitaxel Preclinical Summary
-
04:41
7.
Cabazitaxel in Second-line CRPCTROPIC Phase III Study
-
05:35
8.
Primary Endpoint: Overall Survival Cabazitaxel prolong survival vs. mitoxantrone in p’t progressed on docetaxel
-
06:07
9.
Secondary Endpoint:Cabazitaxel Significantly Improved PFS
-
06:19
10.
Secondary Endpoints:Cabazitaxel Significantly Improved Tumor and PSA Endpoints
-
06:41
11.
Cabazitaxel : Subgroup Analysis of Overall Survival
-
07:26
12.
Patients with initial PSA flare during cabazitaxel therapy are good responders
-
08:14
13.
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with mCRPC: A post-hoc analysis of the TROPIC trial
-
09:14
14.
Cabazitaxel: Main Adverse Events
-
09:49
15.
Management of Select Adverse Events
-
09:50
16.
Cabazitaxel Premedication
-
10:04
17.
Management of Neutropenia*
-
10:17
18.
Growth Factor Support
-
10:47
19.
Comparison of Adverse Events TROPIC vs CUP/EAP
-
11:08
20.
Slide 20
-
11:25
21.
Slide 21
-
11:40
22.
Slide 22
-
11:48
23.
Cabazitaxel remains active in patients progressing after docetaxel followed by abiraterone
-
12:13
24.
Efficacy of Cabazitaxel in CRPC is independent of the presence of AR-V7 in circulating tumor cells
-
12:30
25.
Slide 25
-
12:32
26.
Characteristics of phase III trials examining upfront docetaxel chemotherapy for mHSPC
-
12:48
27.
Current Clinical Trials with docetaxel or Cabazitaxel
-
12:51
28.
Treatment Landscape
- 索引
- 筆記
- 全螢幕
【醫藥護人員場】3. Novel Therapies for Patients with Metastatic Prostate Cancer
長度: 13:41, 瀏覽: 1518, 最近修訂: 2017-05-09
-
00:00
1.
Novel Therapies for Patients with Metastatic Prostate Cancer Part 1Cabazitaxel (Jevtana，去癌達)
-
00:07
2.
Outline
-
00:46
3.
In 2004 docetaxel &predsisone was established as the new standard of care for patients that progressed on ADT
-
02:23
4.
Cabazitaxel (JEVTANA®): a next-generation taxane
-
03:16
5.
Mode of action of Cabazitaxel
-
04:03
6.
Cabazitaxel Preclinical Summary
-
04:41
7.
Cabazitaxel in Second-line CRPCTROPIC Phase III Study
-
05:35
8.
Primary Endpoint: Overall Survival Cabazitaxel prolong survival vs. mitoxantrone in p’t progressed on docetaxel
-
06:07
9.
Secondary Endpoint:Cabazitaxel Significantly Improved PFS
-
06:19
10.
Secondary Endpoints:Cabazitaxel Significantly Improved Tumor and PSA Endpoints
-
06:41
11.
Cabazitaxel : Subgroup Analysis of Overall Survival
-
07:26
12.
Patients with initial PSA flare during cabazitaxel therapy are good responders
-
08:14
13.
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with mCRPC: A post-hoc analysis of the TROPIC trial
-
09:14
14.
Cabazitaxel: Main Adverse Events
-
09:49
15.
Management of Select Adverse Events
-
09:50
16.
Cabazitaxel Premedication
-
10:04
17.
Management of Neutropenia*
-
10:17
18.
Growth Factor Support
-
10:47
19.
Comparison of Adverse Events TROPIC vs CUP/EAP
-
11:08
20.
Slide 20
-
11:25
21.
Slide 21
-
11:40
22.
Slide 22
-
11:48
23.
Cabazitaxel remains active in patients progressing after docetaxel followed by abiraterone
-
12:13
24.
Efficacy of Cabazitaxel in CRPC is independent of the presence of AR-V7 in circulating tumor cells
-
12:30
25.
Slide 25
-
12:32
26.
Characteristics of phase III trials examining upfront docetaxel chemotherapy for mHSPC
-
12:48
27.
Current Clinical Trials with docetaxel or Cabazitaxel
-
12:51
28.
Treatment Landscape
- 位置
-
- 資料夾名稱
- 2016臺大攝護祭-醫藥護人員場
- 發表人
- 系統管理者
- 單位
- 泌尿部
- 建立
- 2016-05-10 12:23:00
- 最近修訂
- 2017-05-09 10:00:23
- 長度
- 13:41